Key Takeaway:
- Eli Lilly Weight-Loss Drug retatrutide helped patients lose up to 28.3% of body weight (70.3 lbs) in a Phase 3 trial, positioning it as one of the most effective obesity treatments to date.
- The drug showed a strong but manageable safety profile, with mostly gastrointestinal side effects like nausea and diarrhea, and no major heart or liver issues reported.
- The results strengthen Eli Lilly’s lead in the obesity drug market, positioning retatrutide as a potential next-generation competitor to existing GLP-1 therapies like Zepbound and Wegovy.
Eli Lilly Weight-Loss Drug retatrutide achieved success in a late-stage Phase 3 trial, delivering up to 28.3% average weight loss over 80 weeks. The results bring the company closer to filing for regulatory approval.
Trial Results Show Significant Weight Loss Across Doses
Eli Lilly Weight-Loss Drug retatrutide, at its highest dose, produced an average weight loss of 28.3% (70.3 pounds) over 80 weeks, compared with 2.2% for placebo among patients who continued treatment. The Phase 3 study included about 2,500 participants.
Roughly 45% of participants achieved 30% or more weight loss, while 65% reached a BMI below 30, Lilly said. Patients with a BMI of 35 or higher in an extension study lost 30.3% of their body weight over 104 weeks.
Chief scientific officer Dan Skovronsky called the 30% weight loss an “incredible number,” saying it has previously only been associated with bariatric surgery. Analysts had expected weight loss to exceed Lilly’s existing drug Zepbound, which delivers about 20% to 22% reduction.
Nearly half of the participants in the trial achieved clinically significant weight loss thresholds that researchers view as potentially surgery-level outcomes. The study is part of a broader late-stage program evaluating retatrutide in obesity and related metabolic conditions. Researchers say the weight loss appears to plateau later in treatment, suggesting sustained efficacy over time.
Side Effects Remain Consistent With GLP-1 Class
The drug’s safety profile aligned with other GLP-1-based therapies, with gastrointestinal side effects most common.
At the highest dose, 42% of patients reported nausea, 32% had diarrhea, and 26.1% experienced constipation. More than 13% experienced upper respiratory infections, and over 12% reported dysesthesia, a nerve-related sensation. More than 8% of patients on the highest dose developed urinary tract infections.
Discontinuation due to side effects reached 11.3% at the highest dose, compared with 4% at the lowest dose and nearly 5% on placebo. No cardiac or liver safety issues were observed in the study.
Chief scientific officer Dan Skovronsky said the lower dose showed a “really excellent tolerability profile.” Analysts had also been watching for cardiac risks due to the drug’s triple-hormone mechanism targeting GLP-1, GIP, and glucagon. Lilly reported no signal of arrhythmia or liver toxicity, easing earlier investor concerns.
Eli Lilly Weight-Loss Drug retatrutide showed that about 45% of participants achieved at least 30% weight loss, underscoring consistency across study endpoints. Experts note that such outcomes could reshape treatment goals for obesity care if confirmed in real-world practice.
Market Stakes Rise as Competition Intensifies
The results strengthen Lilly’s position in the rapidly expanding obesity drug market, where it holds a 60.1% U.S. share compared with Novo Nordisk’s 39.4%. Retatrutide is designed to outperform existing drugs by targeting three hormones instead of one or two.
Eli Lilly Weight-Loss Drug retatrutide is viewed as a successor to Lilly’s Zepbound, which delivers about 20% to 22% weight loss. Analysts at TD Cowen project potential annual sales could reach $3.8 billion by 2030, while broader industry forecasts suggest the obesity and diabetes drug market may approach $100 billion in the 2030s.
Novo Nordisk is developing competing triple-hormone therapies after investing up to $2 billion in an early-stage drug from a Chinese firm. As competition intensifies, companies are racing to develop multi-hormone therapies that may offer greater weight reduction than current GLP-1 drugs.
Lilly executives say retatrutide’s efficacy and tolerability balance will determine how broadly it is adopted once approved. Regulators will now evaluate whether the benefits outweigh gastrointestinal side effects before potential approval filings.
Visit Healthcare 360 Magazine For The Most Recent Information.
